Cortexa Biopharma
Healthy100/100Mid-sizeBiotechnology
About this account
Clinical-stage neuro biotech, ~300 staff, two Phase 2 CNS assets, first EMA filing planned.
Relationship health
100/100 · HealthyHow this account's health has moved over the last 5 weeks.
100 pts0 pts
4w ago2w agothis week
How touches have landed
Every logged touch with Cortexa Biopharma, by outcome.
Interested1100%
Company profile
Not analyzed yet — analyze to qualify its type, ownership and revenue from the web, and the offerings that fit show automatically.
Agent briefing
Cortexa Biopharma is in good shape — healthy, with $260K of open pipeline to grow. It's single-threaded, so widening the relationship would de-risk the deal. Recommended next move: Approve the pitch for Cortexa Biopharma.
HealthHealthy (100/100).
Pipeline1 open deal worth $260K.
ThreadingSingle-threaded on Marcus Thorne — widen the relationship to de-risk.
MomentumLast touch Jul 16, 2026 • 6:00 PM.
Recommended: Approve the pitch for Cortexa Biopharma
Key Contacts
Value PropositionsAI generated
NDA/MAA CMC Writing90% match
Position NDA/MAA CMC Writing against Cortexa Biopharma's near-term regulatory milestones.
Matched from your Freyr knowledge base
Regulatory Intelligence70% match
Single-pane monitoring across FDA, EMA and 120+ agencies.
Matched from your Freyr knowledge base
Angles to researchAI generated
Agent-suggested things worth checking before you reach out — verify before you rely on them.
Regulatory
Check for recent Biotechnology guidance that could tighten their submission timelines — a timely reason to reach out.
Hiring
See whether Cortexa is hiring in regulatory affairs — a growing team often means more submission workload they may need help with.